Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: In vitro studies

Clinical Science

Volumn 103, Issue SUPPL. 48, 2002, Pages

  Wu Wong, J Ruth ^a   Dixon, Douglas B ^a   Chiou, William J ^a   Sorensen, Brian K ^a   Liu, Gang ^a   Jae, H S ^a   Tasker, Andrew ^a   Von Geldern, Thomas W ^a   Winn, Martin ^a   Opgenorth, Terry J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 182086; A 192621; ABT 546; ABT 627; Atrasentan; Endothelin; Endothelin receptor; Endothelin receptor antagonist

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; A 182086; ABT 546; ARACHIDONIC ACID; ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; IODINE 125; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG;

ANIMAL CELL; CHO CELL; CONFERENCE PAPER; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENDOTHELIUM CELL; ISOTOPE LABELING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0036671886     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs103s107s     Document Type: Conference Paper

References (18)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
3. Signal transduction mechanisms mediating the vascular actions of endothelin
4. Purification and characterization of bovine lung endothelin receptor
5. Purification of an endothelin receptor from human placenta
6. Cloning and expression of a cDNA encoding an endothelin receptor
7. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
8. Endothelin and isoproterenol counter-regulate cAMP and mitogen-activated protein kinases
9. Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1
10. Endothelin receptor antagonism
11. A receptor
12. A receptor antagonist
13. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
14. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist
15. A-selective receptor antagonist
16. Endothelin receptor antagonists: A clinical study update
17. Pharmacology of A-216546: A highly selective antagonist for the type-A endothelin receptor
18. Endothelin: New discoveries and rapid progress in the clinic